Characteristics of the subgroups
| Groups | No of patients | Median age at baseline (years) (min, max) | Median duration of BRVO (months) (min, max) | Sex (M/F) |
|---|---|---|---|---|
| Months 1–12 | ||||
| 1st year BEV* | 23 | 68 (45, 80) | 7.1 (3.0, 16.6) | 14/9 |
| 1st year GLP | 21 | 70 (56, 84) | 7.4 (2.9, 18.5) | 11/14 |
| Months 12–24 | ||||
| BEV>GLP | 9 | 69 (64, 84) | 6.0 (3.6, 13.2) | 4/5 |
| GLP>BEV | 6 | 68 (50, 72) | 6.4 (4.5, 16.4) | 4/2 |
*Results previously published.13
BEV, bevacizumab; BRVO, branch retinal vein occlusion; GLP, grid laser photocoagulation.